Reverse Medical Corporation has announced the initial clinical use of their UNO neurovascular embolisation system for intracranial use. The device has been granted European Union CE mark approval to obstruct blood flow in the neurovasculature.
Marco Leonardi at Università di Bologna, Italy performed the initial UNO system clinical case. Leonardi comments, “The UNO represents a unique device, specifically designed for rapid vessel sacrifice, reducing the time otherwise necessary for multiple coil deployments. I can see the UNO becoming a useful tool in my practice. Microcatheter deliverability is excellent within tortuous anatomy, and re-sheathability offers me confidence of placement accuracy.”
According to a press release, Reverse Medical will continue to confirm superior clinical device performance from the UNO System and begin commercialisation in Europe this year through a network of expert regional distributors.
